Evidence map›Paper›PMID 41973703›Full record

ArticlePloS one2026

Multi-task adaptive deep sparse canonical correlation analysis for multi-omics cancer survival prediction.

Yan Wang, Zimo Zou, Yuanyuan Wu, Jing Chen

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yan WangCollege of Life Sciences, Xinyang Normal University, Xinyang, Henan, China.ORCID https://orcid.org/0000-0001-7868-6135
Zimo ZouDepartment of Electrical, Computer and Software Engineering, University of Auckland, Auckland, New Zealand.
Yuanyuan WuCollege of Life Sciences, Xinyang Normal University, Xinyang, Henan, China.
Jing ChenCollege of International Education, Xinyang Normal University, Xinyang, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrating high-dimensional multi-omics data is essential for uncovering the coordinated molecular mechanisms underlying cancer progression and improving survival prediction. DNA methylation and mRNA expression represent two tightly coupled regulatory layers; however, many existing approaches either model them independently or rely on linear assumptions that fail to capture the nonlinear cross-omics structure. Here, we propose MT-ADSCCA, a multitask adaptive deep sparse canonical correlation analysis framework that jointly learns correlated latent representations, selects interpretable multi-omics biomarkers, and supports downstream survival modeling. MT-ADSCCA embeds sparse CCA into a nonlinear encoder architecture and uses uncertainty-guided adaptive weighting to stabilize multi-objective training. The selected features were subsequently modeled using a BiLSTM-Cox survival network with genes ordered by chromosomal coordinates to capture local genomic dependencies. We evaluated MT-ADSCCA using event-stratified nested 10-fold cross-validation across three TCGA cohorts: breast invasive carcinoma (BRCA), glioma (GBMLGG), and pan-kidney carcinoma (KIPAN), including 485, 563, and 652 matched multi-omics samples, respectively. MT-ADSCCA achieved the highest concordance indices across all cohorts, outperforming six feature-selection baselines (DA, WGCNA, lmQCM, CCA, OSCCA, DeepCorrSurv) and four survival-model baselines (LASSO-Cox, RSF, MTLSA, DeepSurv). Kaplan-Meier analyses further confirmed a clear separation between the predicted high- and low-risk groups. The selected canonical features were enriched in biologically coherent functional categories, supporting the interpretability of the learned patterns. Together, these results demonstrate that MT-ADSCCA provides a robust and interpretable framework for multi-omics integration and cancer prognosis prediction.

Indexed as

NeoplasmsBiomarkers, TumorDNA MethylationFemaleGenomicsHumansMultiomicsPrognosisSurvival AnalysisBiomarkers, Tumor

Identifiers

PMID41973703
PMCPMC13075707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.